title: rhBMP-2 release from injectable poly(DL-lactic-co-glycolic acid)/calcium-phosphate cement composites.
abstract: BACKGROUND
  In bone tissue engineering, poly(DL-lactic-co-glycolic acid) (PLGA) microparticles are frequently used as a delivery vehicle for bioactive molecules. Calcium phosphate cement is an injectable, osteoconductive, and degradable bone cement that sets in situ. The objective of this study was to create an injectable composite based on calcium phosphate cement embedded with PLGA microparticles for sustained delivery of recombinant human bone morphogenetic protein-2 (rhBMP-2).
  
  
  METHODS
  (125) I-labeled rhBMP-2 was incorporated in PLGA microparticles. PLGA microparticle/calcium-phosphate cement composites were prepared in a ratio of 30:70 by weight. Material properties were evaluated by scanning electron microscopy, microcomputed tomography, and mechanical testing. Release kinetics of rhBMP-2 from PLGA/calcium-phosphate cement disks and PLGA microparticles alone were determined in vitro in two buffer solutions (pH 7.4 and pH 4.0) for up to twenty-eight days.
  
  
  RESULTS
  The entrapment yield of rhBMP-2 in PLGA microparticles was a mean (and standard deviation) of 79% +/- 8%. Analysis showed spherical PLGA microparticles (average size, 17.2 +/-1.3 micro m) distributed homogeneously throughout the nanoporous disks. The average compressive strength was significantly lower (p < 0.001) for PLGA and calcium-phosphate cement composite scaffolds than for calcium-phosphate cement scaffolds alone (6.4 +/- 0.6 MPa compared with 38.6 +/- 2.6 MPa, respectively). Average rhBMP-2 loading was 5.0 +/- 0.4 micro g per 75-mm (3) disk. Release of rhBMP-2 was limited for all formulations. At pH 7.4, 3.1% +/- 0.1% of the rhBMP-2 was released from the PLGA/calcium-phosphate cement disks and 18.0% +/- 1.9% was released from the PLGA microparticles alone after twenty-eight days. At pH 4.0, PLGA/calcium-phosphate cement disks revealed more release of rhBMP-2 than did PLGA microparticles alone (14.5% +/- 6.3% compared with 5.4% +/- 0.7%) by day 28.
  
  
  CONCLUSIONS
  These results indicate that preparation of a PLGA/calcium-phosphate cement composite for the delivery of rhBMP-2 is feasible and that the release of rhBMP-2 is dependent on the composite composition and nanostructure as well as the pH of the release medium.
authors.forename: P Quinten
authors.initials: PQ
authors.lastname: Ruhe
authors.forename: Elizabeth L
authors.initials: EL
authors.lastname: Hedberg
authors.forename: Nestor Torio
authors.initials: NT
authors.lastname: Padron
authors.forename: Paul H M
authors.initials: PH
authors.lastname: Spauwen
authors.forename: John A
authors.initials: JA
authors.lastname: Jansen
authors.forename: Antonios G
authors.initials: AG
authors.lastname: Mikos
mesh_terms: D001843:Bone Cements; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage / Q000493:pharmacokinetics*; D002130:Calcium Phosphates / Q000008:administration & dosage*; D004337:Drug Carriers; D006016:Glycolates; D006801:Humans; D007267:Injections; D019344:Lactic Acid; D008855:Microscopy, Electron, Scanning; D010316:Particle Size; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000493:pharmacokinetics*; D016212:Transforming Growth Factor beta
chemical_list: C525718:BMP2 protein, human; D001843:Bone Cements; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D002130:Calcium Phosphates; D004337:Drug Carriers; D006016:Glycolates; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid